Loading company…
Percheron Therapeutics develops antisense pharmaceuticals for rare diseases, including candidates for DMD, MS, and acromegaly.
Percheron Therapeutics is developing antisense and other RNA-based or biologic therapies for rare and underserved conditions. Its candidates include ATL1102 for Duchenne Muscular Dystrophy and Multiple Sclerosis, and ATL1103 for Acromegaly. Founded in 2000 in Melbourne, Australia, the company sold Powerhouse Ventures a 5.05% minority stake, or 55 million shares, for AUD 419,310.3 in January 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in